Navigation Links
Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Date:9/19/2007

ounds this year, the expected properties and benefits of its compounds and the results of clinical and other studies. Risks that contribute to the uncertain nature of the forward-looking statements include: risks related to the outcomes of preclinical and clinical trials, risks related to regulatory approvals, delays in commencement of preclinical and clinical tests, and costs associated with internal development and in-licensing activities. These and other risks and uncertainties are described more fully in Ardea's most recently filed SEC documents, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, under the headings "Risk Factors." All forward-looking statements contained in this press release speak only as of the date on which they were made. Ardea undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

* Potent coverage is defined as less than a 10-fold shift in antiviral

activity versus wild-type virus. Prevalence of resistant strains based

on Bachelor et al. Antimicrob Agents Chemother. 2000 Sep; 44(9):

2475-2484.


'/>"/>
SOURCE Ardea Biosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
6. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
7. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
8. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
9. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
10. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
11. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)...  EndoChoice Holdings, Inc. (NYSE:  GI) announced today that ... on Thursday, August 6, 2015 before the market open. ... on Thursday, August 6, 2015 at 9:00 a.m. ET ... 807-9684 for domestic callers and (412) 317-5415 for international ... be available on the investor relations section of the ...
(Date:7/6/2015)... 2015  OrthoSpace Ltd. ("OrthoSpace" or "Company") announced ... in its US Investigational Device Exemption (IDE) pivotal ... single blinded control study that compares the Company,s ... partial repair for the treatment of full thickness ... commercially available outside of the United ...
(Date:7/6/2015)... - The Canadian Pharmacists Association (CPhA) urges the federal government ... all Canadians have the opportunity to protect themselves against ... The lack of access to HPV vaccination programs for ... needlessly putting the health of Canadians at risk. ... pose a significant threat to the health of Canadians," ...
Breaking Medicine Technology:EndoChoice to Report Second Quarter 2015 Financial Results on August 6, 2015 2OrthoSpace Enrolls First Patients in US IDE Study 2CPhA Calls for HPV Strategy for Young Men to Save Lives 2
... MiMedx Group, Inc.  (OTCBB: MDXG), an integrated developer, manufacturer ... processed from human amniotic membrane, announced today its results ... 30, 2011. The Company recorded record revenue ... over second quarter of 2011 revenue of $1,929,000 and ...
... Oct. 26, 2011 Reportlinker.com ... research report is available in ... Early Stage Drug Safety Strategies ... towards achieving clinical success ...
Cached Medicine Technology:MiMedx Group Announces Third Quarter 2011 Results 2MiMedx Group Announces Third Quarter 2011 Results 3MiMedx Group Announces Third Quarter 2011 Results 4MiMedx Group Announces Third Quarter 2011 Results 5MiMedx Group Announces Third Quarter 2011 Results 6MiMedx Group Announces Third Quarter 2011 Results 7MiMedx Group Announces Third Quarter 2011 Results 8MiMedx Group Announces Third Quarter 2011 Results 9MiMedx Group Announces Third Quarter 2011 Results 10Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 2Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 3Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 4Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 5Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 6Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 7Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 8
(Date:7/7/2015)... ... , ... Dr. Poneh Ghasri , cosmetic dentist in Los Angeles, is ... one of the fastest, easiest ways to brighten a smile. Stained teeth can add ... confidence. With the right teeth whitening treatment, patients can restore a more youthful appearance ...
(Date:7/7/2015)... ... 2015 , ... Office Practicum announced today that it has ... effective July 6th, 2015. Ellen joins Office Practicum with more than 27 years ... chemical company to early and growth-stage technology companies. , Purdy joins Office ...
(Date:7/7/2015)... ... July 07, 2015 , ... ISI ... announced the release of Service Pack 5600 for its Call Accounting and ... enhancements to the already robust capabilities of the reporting platform, including updates ...
(Date:7/7/2015)... (PRWEB) , ... July 07, 2015 , ... Connexion Point is holding an onsite job ... be held at 1769 Paragon Place, Suite 100, this upcoming Wednesday, July 8, and Thursday, ... fair, Connexion Point will be recruiting new applicants as well as holding onsite interviews. ...
(Date:7/6/2015)... Angeles, CA (PRWEB) , ... July 06, 2015 , ... ... for finding medical providers for personal injury victims. Throughout the company’s history the ... collectively deliver the care victims need in their recovery. And while Doctors on ...
Breaking Medicine News(10 mins):Health News:Los Angeles Cosmetic Dentist, Poneh Ghasri DDS, Now Offers Promotions on Whitening Treatments 2Health News:Los Angeles Cosmetic Dentist, Poneh Ghasri DDS, Now Offers Promotions on Whitening Treatments 3Health News:Office Practicum Announces new CFO 2Health News:ISI Telemanagement Solutions, Inc. Releases Service Pack 5600 for Infortel® Select 2Health News:Connexion Point, a tech enabled healthcare services company, is holding on-site job fair July 8th and 9th to fill 400 positions at its new Memphis location 2Health News:Doctors on Liens Adds Transportation to Its Ever-Expanding Network 2Health News:Doctors on Liens Adds Transportation to Its Ever-Expanding Network 3
... April 30 Retirement Living TV (RLTV) ... to bring a compelling,dialogue on the healthcare ... Virginia and Southern Delaware television markets through ... The nation,s leading,political and public leaders present ...
... April 30 Brown & Toland Medical Group,today announced ... of $12 million on total revenues of $235 million., ... million for,pay for performance and other related bonuses from ... distribute an additional $8.2,million in bonus payments to eligible ...
... study finds antidepressant cut inflammation in relapsing remitting ... may help reduce disease activity in people with the ... study suggests. , Forty patients with the disease were ... of fluoxetine (Prozac) or a placebo for 24 weeks. ...
... in heart rate variability, researchers report, , , WEDNESDAY, April ... show that the electromagnetic field produced by incubators affect ... , Whether these changes in cardiac rhythms have long-term ... premature infants who can spend several weeks or months ...
... during its Q1 2008 ... conference call on May 8 -, ... the "Company") (NASDAQ: SXCI , TSX: SXC), a leading provider,of ... (NASDAQ: NMHC ), announce that the previously,announced acquisition of NMHC ...
... to Both Reduce Exacerbations ... and Improve Lung Function, ... and Drug Administration today approved Advair Diskus(R) 250/50,(fluticasone propionate 250 ... exacerbations in patients with chronic obstructive,pulmonary disease (COPD) who have ...
Cached Medicine News:Health News:Retirement Living TV Partners with Maryland Public Television to Address the Issue of Healthcare in America Through Its Series Healthcare '08: Search for Solutions 2Health News:Retirement Living TV Partners with Maryland Public Television to Address the Issue of Healthcare in America Through Its Series Healthcare '08: Search for Solutions 3Health News:Brown & Toland Announces 2007 Financial Results 2Health News:Prozac Reduces Disease Activity in MS Patients 2Health News:Incubators Affect Newborns' Heart Rates 2Health News:SXC Health Solutions completes acquisition of NMHC 2Health News:FDA Approves Advair(R) 250/50 for Reduction of Exacerbations in Patients With COPD 2Health News:FDA Approves Advair(R) 250/50 for Reduction of Exacerbations in Patients With COPD 3Health News:FDA Approves Advair(R) 250/50 for Reduction of Exacerbations in Patients With COPD 4
The IntraStent DoubleStrut Biliary Stent represents a completely new direction in stent design. The combination of parallel struts and unique cell geometry provide unparalleled performance....
The Smart Check Syphilis Device is a qualitative membrane device based immunoassay for the detection of TP (Treponema Pallidum) antibodies in whole blood/serum/plasma. For professional in vitro diagn...
Bio-Quant, Inc. OneStep hCG InstaTest is an immunochromatographic assay designed for qualitative determination of human chorionic gonadotropin (hCG) in urine for early detection of pregnancy....
OneStep Midstream Urine hCG Pregnancy InstaTest is a test kit for the determination of hCG(Human Chorionic Gonadotropin) in urine specimens. This test kit is used to obtain a visual, qualitative resu...
Medicine Products: